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ABSTRACT
In recent years the availability of several
tyrosine kinase inhibitors (TKI) in the
therapeutic armamentarium for chronic
myeloid leukemia has dramatically changed
the objectives and expectations of healthcare
providers and patients. For many, but not all,
patients the forerunner of TKI, imatinib, is still
an excellent treatment option. Unfortunately,
nearly 30–40% of imatinib-treated patients
discontinue therapy in the long-term, because
of failure and/or intolerance. Second-generation
tyrosine kinase inhibitors are more potent drugs
which are suitable for treatment of
approximately 50% of patents for whom
imatinib is unsuitable, and with high success
and rapid responses. Bosutinib, an orally
bioavailable Src/Abl tyrosine kinase inhibitor,
has proved to be effective in vitro against
resistant chronic myeloid leukemia cells that
do not harbor the T315I or V299L ABL kinase
domain mutations. During clinical
development the manageable safety profile of
bosutinib have become evident for both simple
and more advanced treatment. In this review we
summarize preclinical and clinical data for
bosutinib and discuss its ideal field of action
in comparison with other TKI.
Keywords: Bosutinib; Chronic myeloid
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INTRODUCTION
The Src and Abl families of non-receptor protein
tyrosine kinases have been extensively studied as
targets for anticancer therapy because of their
involvement in signaling pathways promoting
tumor growth and progression [1–3]. Moreover,
the presence of the constitutively active chimeric
protein BCR-ABL, an oncogenic product arising
from reciprocal translocation between
chromosomes 9 and 22 (Philadelphia
chromosome) [4], is regarded the pathogenetic
characteristic of chronic myeloid leukemia (CML).
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Selective inhibition of BCR-ABL
autophosphorylation and phosphorylation of
its substrates by tyrosine kinase inhibitors (TKI)
resulted in a substantial and dramatic
improvement of survival of CML patients, and
has become one of the most important
examples of target therapy [5].
Nowadays, paradoxically (although luckily)
treatment of CML has become more
complicated, because of the availability of
second and third-generation TKI, which are
used as both salvage therapy and alternative
simple options [6].
Several studies have confirmed the long-term
efficacy and manageable safety profile of
imatinib, the first approved TKI. However,
approximately 40% of patients have to switch
to different treatment because of intolerance or
resistance [7, 8]. Second-generation TKI have
resulted in a favorable outcome for
approximately half of non-responding patients
after primary or secondary resistance [9, 10]. In
addition, use of new TKI as initial treatment
resulted in improved efficacy with evidence of
an extremely good molecular response and
lower progression, irrespective of features and
risk at diagnosis, but with inconsistent
long-term overall survival compared with
imatinib [11, 12].
Bosutinib, a second-generation dual
inhibitor of Src and Abelson (Src/Abl) kinases,
is currently approved in Europe and USA for
treatment of adult patients with chronic phase
(CP), accelerated phase (AP), and blast phase
(BP) Philadelphia chromosome-positive CML
previously treated with one or more TKI and
for whom imatinib, nilotinib, and dasatinib are
not regarded as appropriate treatment options.
The purpose of this review is to focus on efficacy
and safety data for bosutinib for treatment of
resistant and/or intolerant CML or for newly
diagnosed CP-CML patients.
This article is based on previously conducted
studies and does not include any new studies of
human or animal subjects performed by any of
the authors.
MECHANISM OF ACTION
Bosutinib is an orally bioavailable 4-[(2,4-
dichloro-5-methoxyphenyl)amino]-6-methoxy-7-
[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-
carbonitrile originally identified by Boschelli, in
2001, to act as a Src tyrosine kinase inhibitor
[13]. Two years later, Golas documented potent
antiproliferative and pro-apoptotic activity of
bosutinib, at concentrations between 1 and
20 nM, against CML culture (K562, KU812,
and Meg-01) [14]. Reduced BCR-ABL, CrkL,
STAT5, and Lyn phosphorylation were
consistent with both Src and Abl kinase
inhibitory activity. Bosutinib was
demonstrated to bind the kinase domain of
BCR-ABL in an active or inactive conformation.
Puttini and colleagues reported the activity of
Bosutinib against BaF3 murine myeloid cells
expressing resistant forms of BCR-ABL, with
mutations Y253F, E255K, and D276G; no
inhibition was observed against cells
expressing the T315I or V299L mutation [15].
Later studies by Konig et al. focused on
bosutinib activity against specific CML
progenitors, and reported effective BCR-ABL
and Src kinase inhibition in CML progenitor
cells and growth suppression of CML primitive
and committed progenitor cells. However,
bosutinib did not significantly inhibit
non-dividing CML primitive progenitors [16].
In 2009, by use of a chemical proteomics
approach in combination with in-vitro kinase
assays against a large number of recombinant
kinases, Remsing Rix provided more insight
into bosutinib’s kinase target profile. Bosutinib,
similar to dasatinib, was shown to target TEC
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family kinases, including BTK; however, in
contrast with dasatinib, bosutinib did not
inhibit KIT or PDGFR, but rather had activity
against the STE family of kinases, in particular
the STE20 subfamily. CAMK2G, a
Ca2?/calmodulin-dependent protein kinase
was also identified as a novel kinase target
inhibited by the drug [17].
PHARMACOKINETIC DATA
The pharmacokinetic (PK) profile of the drug in
the orally bioavailable form was extensively
studied in phase I/II trials among either adult
healthy volunteers of cancer patients.
Population PK analysis of three clinical studies
among patients with cancer suggested that
baseline characteristics (age, body weight,
gender and race) did not affect the PK data.
Drug absorption was relatively slow, with a
median time to peak concentration of 4–6 h and
a half life t1/2 ranging from 33 to 39 h, thus
supporting a once-daily dosing regimen [18].
The effect of food was studied among 55
healthy subjects randomly assigned to receive
bosutinib 200, 400, 600, or 800 mg with food or
200 or 400 mg without food, or placebo [19].
Significant increase in bosutinib exposure was
observed for maximum serum concentration
(Cmax), and area under the curve (AUC)
increased by 1.6–1.7-fold when taken with
food, the effect being more evident at lower
doses. The interaction, resulting in increased
drug exposure, was explained by an increase in
bosutinib solubility when taken with food [19].
After administration of a single dose of
500 mg bosutinib, mean apparent volume of
distribution for patients with CML was
6080 ± 1230 L, which correlated with
extensive partitioning into tissues. Bosutinib is
highly bound to human plasma proteins
in vitro (94%) and ex vivo in healthy subjects
(96%), and binding was not concentration-
dependent. The major circulating metabolites
identified in plasma were oxydechlorinated
(M2) bosutinib (19% of parent exposure) and
N-desmethylated (M5) bosutinib (25% of parent
exposure), with bosutinib N-oxide (M6) a minor
circulating metabolite. All the metabolites were
inactive [20].
For patients with CML given single oral doses
of 500 mg bosutinib with food, the mean
terminal phase elimination half-life was
22.5 h; 91.3% of the dose was recovered in the
feces and 3% in the urine. Undergoing
extensive first-pass-metabolism, bosutinib was
deemed to interact with CYP3A inducers and
inhibitors. Early studies showed that bosutinib
is primarily metabolized by hepatic CYP3A4. In
a trial of 24 healthy volunteers, a single dose of
100 mg bosutinib was administered either alone
or in combination with 5 daily doses of 400 mg
ketoconazole under fasting conditions.
Ketoconazole increased bosutinib Cmax and
AUC 5.2-fold and 8.6-fold, respectively.
Moreover, co-administration reduced the
mean apparent clearance of bosutinib
approximately ninefold and increased the
mean terminal half-life from 46.2 to 69.0 h.
Despite this increase in bosutinib exposure, the
incidence of adverse side effects was comparable
with that for administration of bosutinib alone
[21]. In a cross-over trial of 24 healthy
volunteers, a single dose of 500 mg bosutinib
was administered alone or in combination with
six daily doses of 600 mg of rifampicine, a
potent CYP3A4 inducer, under fed conditions.
Rifampicine decreased bosutinib Cmax and AUC
by 86% and 94%, respectively [22]. According to
these data, concurrent use of bosutinib with
strong or moderate CYP3A inhibitors (and
inducers) should be avoided whenever
possible. Furthermore, P-glycoprotein (P-gp)
inhibitors and grapefruit or grapefruit juice
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should be avoided because their administration
may result in increased drug plasma
concentrations. In-vitro data showed no effect
of bosutinib as an inducer or inhibitor of the
metabolic liver enzymes CYP1A2, CYP2A6,
CYP2C8, CYP2C9, CYP2C19, CYP2D6, or
CYP3A4.
Interaction of bosutinib with
gastroprotective drugs was tested in a trial
with 24 healthy fasting subjects. A single
400-mg dose of bosutinib was given
concurrently with repeated doses of
lansoprazole 60 mg. Bosutinib Cmax and AUC
decreased by 46% and 26%, respectively [23].
Therefore, concomitant administration of
proton-pump inhibitors with bosutinib should
be avoided whenever possible; otherwise,
short-acting antiacids or histamine-2 receptor
antagonists should be considered if taken 2 h
before or after bosutinib.
The relationship between bosutinib exposure
at steady state and most common adverse side
effects (i.e., diarrhea, thrombocytopenia, rash,
transaminases (ALT/AST) increase, nausea,
vomiting, and neutropenia) was recently
investigated by Hsyu et al., who combined data
from phase III and phase I/II clinical studies on
749 patients with newly diagnosed CP-CML or
with CP-CML resistant and/or intolerant to
previous imatinib therapy, respectively [24].
Associations between bosutinib exposure at
steady state and key efficacy endpoints from
each of the two studies were also investigated.
An exposure–response relationship was
identified for the incidence (but not severity) of
diarrhea; a weak relationship was also observed
for the incidence of rash. No evidence of an
exposure–response relationship was documented
for nausea, vomiting, neutropenia,
thrombocytopenia, or liver enzymes elevation.
For patients with newly diagnosed CP-CML,
exposure–response relationships were observed
for complete cytogenetic response at 1 year
(predicted probability, 0.476–0.650), major
molecular response (MMR) at 1 year
(0.238–0.497), and cumulative complete
hematologic response (CHR) at 1 year
(0.605–0.763). For patients with previously
treated CP-CML, no exposure–response
relationship was observed for major cytogenetic
response (MCyR) at 24 weeks (0.320) [24].
Pharmacokinetic of bosutinib in the context
of hepatic impairment was investigated in a
dedicated trial in which a single dose of 200 mg
was administered with food to 18 volunteers
with A, B, and C Child-Pugh classes and to 9
matched healthy volunteers. Cmax of bosutinib
was found to be increased 2.4-fold, twofold, and
1.5-fold, respectively, for Child-Pugh classes A,
B, and C, and bosutinib AUC increased 2.3-fold,
twofold, and 1.9-fold, respectively. On the basis
of these data, use of bosutinib is contraindicated
in Europe for patients with hepatic impairment
[25].
The effect of renal impairment on bosutinib
pharmacokinetic profile was evaluated in a
phase-1 two-stage trial in which a single dose
of 200 mg was administered, with food, to 26
subjects with mild (CLcr 51–80 mL/min),
moderate (CLcr 30–50 mL/min), or severe
(CLcr\30 mL/min) renal impairment and to 8
subjects with normal renal function. Although
bosutinib exposure was unchanged for subjects
with mild renal impairment, moderate and
severe renal impairment were associated with
increases in AUC of 35% and 60%, respectively,
compared with subjects with normal renal
function. Specific recommendations
concerning dose adjustment were made for
patients with severe (CLcr \30 mL/min) or
moderate (CLcr between 30 and 50 mL/min)
renal impairment [26].
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PHASE 1/2 STUDY: CLINICAL
EFFICACY
In the phase 1 portion of a phase 1/2 study that
enrolled imatinib-treated CML patients, the
bosutinib dose of 600 mg/d was the maximum
tolerated dose. Part 1 was a dose-escalation study
with 3 ? 3 design with subsequent cohorts of
3–6 imatinib-resistant patients. The dose of
500 mg once-daily was selected for phase 2 of
the trial; the trial was later amended to include
nilotinib and dasatinib-treated patients when
these drugs became commercially available.
Escalation to 600 mg daily was allowed after
lack of efficacy (failure to achieve CHR by week 8
or complete cytogenetic response (CCyR) by
week 12). Imatinib resistance was defined as no
hematological improvement within 4 weeks, no
CHR by 3 months, no cytogenetic response by
6 months, or no MCyR by 12 months, for at least
600 mg imatinib daily. Imatinib intolerance
was defined as grade IV hematologic toxicity
lasting for more than 7 days, grade 3–4
non-hematological toxicity, or grade 2 toxicity
that did not improve despite adequate
management or adjustment of the dose of the
drug. The primary endpoint of the study was
MCyR at 24 weeks for patients with no previous
TKI exposure other than imatinib.
Part 1 included 17 patients with imatinib
resistance in the chronic phase and 1
accelerated-phase patient: bosutinib was well
tolerated without dose limiting toxicity (DLT)
in the 400–500 mg cohorts; indeed, in the
600 mg cohort, one patient developed
vomiting, rash, and nausea related to the drug.
In the second part of the trial, the median dose
intensity reported was 484.9 mg/day for
imatinib-resistant and 394.1 mg/day for
imatinib-intolerant patients.
Overall, for the 200 imatinib-resistant and 88
imatinib-intolerant CP-CML patients enrolled
in this trial, after 1 year, CHR was achieved for
86% of imatinib-resistant and 85% of
imatinib-intolerant patients; this was sustained
for 72% and 87%, respectively and was obtained
in a median time of 2 weeks. Fifty-four percent
of imatinib-resistant and 49% of
imatinib-intolerant patients had a decrease in
Ph? metaphases to\35% (MCyR); this was
maintained for 72% of imatinib-resistant and
92% of imatinib-intolerant patients. Median
time of MCyR was 12.3 weeks. CCyR was
detected in 41%; among those patients who
achieved CCyR and were evaluable for
molecular response, 64% of imatinib-resistant
and 65% of imatinib-intolerant patients
achieved a MMR. Complete molecular
response (CMR) was achieved by 49% and 61%
of patients, respectively [27]. Mutational
analysis was assessed for 115 patients at
baseline (most frequently observed M351T,
F359V, F317L, L248V, G250E, M244V, T315I)
and responses were observed for all mutants
except T315I [27]. At 1 year, progression-free
survival (PFS) was 91% and overall survival (OS)
was 97% [27]. After 2 year, CCyR was 48% and
MMR was 35%, not expressed on international
scale (IS), with 28% of patients achieving CMR.
Median time reported to achieve MMR was
35.9 weeks for imatinib-resistant and
12.2 weeks for imatinib-intolerant patients. At
2 years, PFS was 81%; progression to blast phase
occurred for 11 patients and 2-year OS was 91%
[28] (Table 1).
Long-term outcome for patients treated in
the advanced phase of disease has recently been
reported for 79 patients in the accelerated phase
(AP), 64 in the blast phase (BP), and 24 with
acute lymphoblastic leukemia (Ph? ALL). After
4 years, 14 AP, 2 BP, and 1 ALL patients
remained in the study, with a median
duration of treatment of 10.2 months. Among
AP patients, 57% achieved an overall
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hematologic response and 40% a MCyR with a
4-year probability of maintaining this response
of 65%; among BP patients, 28% achieved an
hematologic response and 37% a MCyR with a
21% probability of 4-year duration. Responses
were durable, suggesting possible use of this
drug while awaiting transplant [29].
SAFETY OF PHASE 1/2 STUDY
The most common adverse side effects observed
were gastrointestinal, for example diarrhea,
nausea, vomiting, abdominal pain, rash, fever,
fatigue and increased alanine aminotransferase.
Most frequent grade 3/4 side effects were low
incidence of diarrhea, increased ALT, and rash.
Only 3% of patients experienced a pleural
effusion related to the drug. Gastrointestinal
side effects occurred early, and usually of low
severity; transient diarrhea was managed with
loperamide in 69% of cases, with temporarily
interruptions in 15% of cases, or reduction of
dose for 6% of patients. Forty-five percent of
patients used antiemetic for nausea and 33% for
vomiting. Cardiac side effects were reported for
14% of patients, the most frequent being atrial
fibrillation and palpitations; two patients
discontinued as a result of cardiac side effects
and one died of unrelated cardiac failure. With
regard to hematologic toxicity, 24% of patients
experienced grade 3/4 thrombocytopenia in a
median time of 21 days, whereas 17%
experienced grade 3/4 neutropenia and 8%
anemia (Fig. 1). The most frequent laboratory
abnormalities were elevated ALT (58% overall
and 10% as grade 3/4), hypophosphatemia
(43% overall and 9% as grade 3/4), and
elevated lipase (28% overall and 8% as grade
3/4). Also in the advanced phase of the disease,
the most common side effects were
gastrointestinal with diarrhea among 85% of
AP patients and among 64% of BP patients,
mostly of grade 1/2. The most common serious
adverse side effects reported were pneumonia
Table 1 Best overall response observed for bosutinib-treated patients, for both ﬁrst and subsequent treatment
Response
(% of evaluable patients)
Phase I/II trial [26, 27] BELA trial [29, 30]
IMA-R (n5 200) IMA-I (n5 88) Bosutinib (n5 248) Imatinib (n5 251)
CHR 24 months 85 82 NR NR
CCyR 12 months 36 50 70 68
24 months 46 54 87 81
MMR 12 months 22 31 41 27
24 months 29 31 59 49
CMR 12 months 16 13.5 12 3
24 months 25 32 NR NR
PFS 95 91 NR NR
Progression to AP/BP 5 1.1 2 5
OS (24 months) 98 89 97 95
AP/BP accelerated/blastic phase, BELA bosutinib efﬁcacy and safety in newly diagnosed CML, CCyR complete cytogenetic
response, CHR complete hematological response, CMR complete molecular response, IMA-I imatinib-intolerant,
IMA-R imatinib-resistant, MMR major molecular response, PFS progression-free survival, NR not reported, OS overall
survival
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among AP patients (9 patients) and pyrexia for 6
BP patients [27] (Table 2).
BOSUTINIB FOR NEWLY
DIAGNOSED CML PATIENTS
The BELA study was a phase 3 randomized trial
that compared bosutinib with imatinib for
newly diagnosed CP-CML patients [30]. Five
hundred and two patients were randomly
assigned 1:1 to bosutinib at a dose of 500 mg
per day or imatinib at 400 mg per day.
Follow-up at 1 year reported CCyR, the
primary endpoint of the study, of 70% for
bosutinib and 68% for imatinib, without
significant difference. Median time to achieve
CCyR was faster with bosutinib. MMR was
higher for bosutinib (41% compared with 27%
for imatinib) and CMR was also higher for
bosutinib (12% versus 3%). The median time
to reach MMR was faster with bosutinib,
37 weeks compared with 72.3 weeks with
imatinib. No differences were observed for
different Sokal risk groups. Eleven side effects
were recorded for bosutinib and 18 for
imatinib, with estimated side-effect-free
survival of 94% and 93%, respectively. Two
percent of patients with bosutinib experienced
progression, compared with 10.4% in the
imatinib group [30].
Recently, the trial was updated at 24 months:
CCyR was 79% with bosutinib and 80% with
imatinib, whereas MMR was 59% and 49%,
respectively. Responses were durable and since
the previous report at 1 year no new cases of
progression were detected with bosutinib
whereas another four cases were observed with
imatinib [31] (Table 1).
Fig. 1 Suggested management of the most frequent adverse side effects for patients treated with bosutinib
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SAFETY OF BOSUTINIB AMONG
NEWLY DIAGNOSED CP PATIENTS
A recently published update of the BELA trial
reported safety analysis after more than
30 months of follow-up. In the bosutinib
group gastrointestinal side effects were more
frequent, for example diarrhea 70% compared
with 26% in the imatinib arm and vomiting in
33% versus 16%, respectively. As in the phase
1/2 trial, elevation of alanine aminotransferase
and aspartate aminotransferase was observed in
the bosutinib group (33% and 28% versus 9%
and 10%, respectively). Less common with
bosutinib were recorded edema (7% versus
26%), musculoskeletal pain (cramp 5% versus
22%, bone pain 4% versus 11%), and
neutropenia (13% v3ersus 30%). No significant
difference was noted between the two groups.
Gastrointestinal events were usually transient,
manageable with concomitant medications,
and usually occurred during the first months
of treatment. In particular, diarrhea was
managed by dose modification and/or
concomitant medication [33] (Table 2).
CARDIOVASCULAR SAFETY
ANALYSIS
Retrospective analysis evaluating cardiac
toxicity data from the 2 studies (BELA and
study 200) has been reported. Patients were
excluded at study entry if they required
medications that prolong the QT interval, had
a history of significant/uncontrolled cardiac
disease (congestive heart failure, uncontrolled
angina, or hypertension within 3 months,
myocardial infarction within 12 months,
Table 2 Adverse side effects associated with bosutinib treatment among imatinib-resistant, imatinib-intolerant, or
previously untreated patients with chronic myeloid leukemia
Adverse side effects %
All (% G3–4)
Phase I/II trial [27] BELA trial [30]
IMA-I (n5 88) IMA-R (n5 200) Bosutinib (n5 248) Imatinib (n5 251)
Thrombocytopenia 66 (21) 70 (32) 28 (13) 28 (14)
Anemia 91 (12) 86 (18) 25 (8) 22 (6)
Neutropenia 49 (14) 51 (24) 13 (8) 29 (16)
Diarrhea 84 (9) 85 (13) 70 (12) 25 (1)
Nausea 42 (0) 51 (5) 32 (1) 36 (0)
Vomiting 35 (2) 41 (9) 32 (3) 16 (0)
Rash 32 (9) 41 (11) 24 (2) 19 (1)
Pyrexia 27 (1) 16 (0) 18 (1) 12 (1)
Abdominal pain 23 (1) 25 (2) 13 (1) 7 (\1)
Fatigue 23 (1) 25 (2) 13 (1) 14 (1)
Elevated AST 49 (4) 55 (7) 27 (8) 9 (3)
Elevated ALT 55 (10) 66 (11) 32 (18) 8 (3)
Elevated creatinine 37 (1) 41 (0) NR NR OK
AST aspartate aminotransferase, ALT alanine aminotransferase, BELA bosutinib efﬁcacy and safety in newly diagnosed
CML, IMA-I imatinib-intolerant, IMA-R imatinib-resistant, NR not reported
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clinically significant ventricular arrhythmia,
diagnosis or suspected congenital or acquired
prolonged QT syndrome, history of prolonged
QTc, or unexplained syncope), or had average
QTc[0.45 s at screening or uncorrected
hypomagnesemia or hypokalemia.
Treatment-emergent adverse side effects were
monitored throughout the studies and coded
according to NCI CTCAE version 3.0.
Incidence of exposure-adjusted cardiac
adverse side effects was 0.059 for bosutinib
and 0.042 for imatinib in the phase 3 BELA
study and 0.096 for bosutinib in the phase 1/2
study. The most common cardiac side effect
experienced by bosutinib-treated patients in
both studies was cardiac arrhythmias (5.7%
overall; grade 3/4, 1.5%). Cardiac arrhythmias
occurred for 4.0% and 2.0% (grade 3/4, 0.4%
and 0%) of bosutinib-treated and
imatinib-treated patients, respectively, in the
phase 3 BELA study, and in 6.5% (grade 3/4,
1.9%) of bosutinib-treated patients in the phase
1/2 study.
Incidence of heart failures was uncommon
overall (2.9% of all bosutinib-treated patients;
grade 3/4, 1.7%); it was similar for bosutinib
(0.8%; grade 3/4, 0.8%) and imatinib (0.8%;
grade 3/4, 0%) in the phase 3 BELA study. The
incidence of newly emergent side effects
decreased with longer duration of treatment.
In the phase 3 BELA study, discontinuations
because of cardiac side effects were numerically
higher for bosutinib-treated than for
imatinib-treated patients (1.6% versus 0%,
respectively). Reasons for discontinuation for
the 4 bosutinib-treated BELA patients were
pericardial effusion, right bundle branch
block, congestive cardiac failure, and ECG QT
prolonged.
In both bosutinib studies, few patients
(2.0%; grade 3/4, 0.9%) discontinued bosutinib
because of cardiac side effects.
In the phase 3 BELA study cardiac side
effects leading to dose delays were not
significantly more frequent among
bosutinib-treated patients than among
imatinib-treated patients (3.6% versus 1.6%,
respectively; grade 3/4, 0.8% versus 0%). Of 32
patients from both studies whose bosutinib
dose was delayed because of adverse side
effects, 26 were re-challenged and 6
discontinued bosutinib permanently because
of a cardiac side effect.
Analysis of predisposing factors to cardiac
events showed that age[65 years, previous
history of cardiac disorders, ECOG[0 in the
phase 1/2 study and history of hypertension in
phase 3 trial, or hypercholesterolemia (in both
studies) were significantly associated. Indeed,
the incidence of vascular emergent side effects
with bosutinib was comparable with that with
imatinib in the BELA study [33]. With the
exception of hypertension, which was
common with bosutinib (in a combined
analysis any grade\7%; grade 3/4\2%), the
incidence of vascular side effects was
particularly low [34].
CROSS-INTOLERANCE BETWEEN
BOSUTINIB AND PREVIOUS TKI
Analysis was conducted to investigate the
potential cross-intolerance of bosutinib with
previous TKI when used as second or third line
treatment. Of 143 patients previously treated
with imatinib, 22 (20 in CP and 2 in advanced
phase) discontinued the drug for the same
effect (prevalently cytopenias). Seventy-one
patients previously treated with dasatinib
received bosutinib for intolerance: 7 patients
in CP and 1 in AP experienced the same side
effect (thrombocytopenia and pleural
effusions).
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Of 7 patients intolerant of nilotinib, 3
patients then discontinued bosutinib for
thrombocytopenia also experienced as a result
of the previous treatment. This data showed the
absence of cross-intolerance between bosutinib
and the other drugs [35].
WHICH IS THE IDEAL PLACE
FOR BOSUTINIB IN THE CONTEST
OF SEVERAL CHOICES?
Considering that agreement on the application
of each TKI for management of CML is far from
being established, personal perspectives rather
specific recommendations for bosutinib use can
be drawn.
Undoubtedly, one advantage of this drug is
its favorable safety profile. A low incidence of
some adverse side effects common with other
TKI makes bosutinib a good choice for patients
intolerant to other TKI with comorbidities or
cardiovascular risk factors. Moreover, bosutinib
is active against many BCR-ABL kinase domain
mutations resistant to imatinib, dasatinib, and
nilotinib, with the exception of T315I and
V299L.
Patients who experience treatment failure
with a second-generation TKI (2G-TKI) as first or
second-line treatment seem to gain limited
benefit from sequential use of 2G-TKI; Lipton
and colleagues recently reviewed published data
and concluded that the probability of complete
cytogenetic response ranged from 22% to 26%
for the 2G-TKI examined [36].
In conclusion, with the increasing
therapeutic options available for CML and
continually increasing treatment objectives,
healthcare providers have the opportunity to
design patient-tailored strategies in accordance
with individual characteristics such as age,
comorbidities, life-style, treatment history,
disease stage, and TKI toxicity profile.
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